EMPA-ESUS. a Randomised Control Trial to Investigate the Impact of Empagliflozin on Left Atrial Function in Patients with Embolic Stroke of Undetermined Source

PHASE2/PHASE3RecruitingINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

November 22, 2024

Primary Completion Date

July 31, 2026

Study Completion Date

March 31, 2029

Conditions

Embolic Stroke of Undetermined SourceAtrial Fibrillation New Onset

Interventions

DRUG

Empagliflozin 10 MG

Participants allocated in the Intervention Group will be taking empagliflozin 10mg once a day in addition to their usual stroke care.

Trial Locations (1)

RECRUITING

Addenbrookes Hospital, Cambridge

All Listed Sponsors

collaborator

Addenbrookes Hospital, Cambridge

UNKNOWN

lead

University of East Anglia

OTHER